Will the DJIA Reach 40,000 this decade? And What Could Drive Market Growth?
New feature report will be issued tomorrow 12-7-20 at market open
Good day breakout group,
The markets are strong.
We’ve seen the DJIA pass 30,000 (30,218) and continue to hover in that range. We’ve seen the NASDAQ holding steady above 12,000 (12,464) and the S&P 500 is over 3,600 (3,699). The markets have confounded many given the health and social difficulties presented in 2020.
So, what could be driving the markets? Is there some impetus that could drive the DJIA to 40,000?
The sector’s we expect could experience strong growth through the 2020’s and be the main driver of growth in the markets are biotech, commodities and disruptive technologies.
Biotech Advancements
In the year 2000, scientists were able to map the human genome after fifty years of trying. Their success was fueled by computers that had become equal to the task.
At the time, way back in 2000, pundits in the medical sector predicted the newly discovered data on the human genome would likely not bear fruit for another 20 years. Well…here we are.
Medicine is on the cusp of exciting treatments and cures. The days of pills, powders, and potions are slipping away and being replaced by stem cell therapies, monoclonal antibodies, mRNA applications and gene splicing just to mention a few. These new therapies are in clinical trials being conducted across the globe.
Recently, President Trump received monoclonal stem cell therapy for covid-19 and all the upcoming vaccines for covid-19 are mRNA based. We believe that amazing medicines, treatments, and procedures will come to fruition in the coming decade.
Much of the excitement in biotech will come from the symbiotic relationship between small cap companies on the NASDAQ and big pharma companies. Innovative small caps will continue to create new products and collaborate with big pharma in the development stage.
Biotech stocks may very well be a major market leader because that is the sector where a lot of innovation takes place, and we expect a rash of M&A activity throughout the decade. While the biopharma industry has been absorbed with covid-19 we have seen many programs and clinical trials for treatment programs for other diseases slow down.
In 2019 M&A activity in the biotech sector exceeded $350 billion. We anticipate a lower number in 2020 due to the slowdown of virtually everything during the pandemic. According to PwC group, biotech M&A activity in 2021 and beyond may be focused on these types of companies:
• Mid-size biotech companies, such as cell and gene therapy, oncology, and next-generation biologics, will continue to attract interest from big pharma. Research and development (R&D) and technical expertise will be key drivers.
• Medical devices, vaccines, therapies, and diagnostics connected to pandemic response and future preparedness are expected to have attractive value creation stories and become targets for acquisitions and tie-ups.
• Device manufacturers (and certain drug companies) across a variety of therapeutic areas not related to COVID-19 (including dental, general surgery and orthopedics have faced significant challenges due to restrictions on elective procedures and we expect this to result in consolidation.
• Acquisitions that PLS companies can integrate to pivot their business models towards more digital delivery should see strong interest.
The development of covid-19 vaccines(s) in under a year, or at “warp speed” may have a permanent impact on the FDA and clinical trials. Perhaps we will apply the warp speed mandate to diseases such as cancer that kills hundreds of thousands per year.
We will be keeping a sharp eye on the biotech sector, as the decade progresses. Stay tuned, we are looking at some right now.
New report coming at market open tomorrow 12-7-2020.
Stay tuned and stay informed,
The Traders News Group
We thought some of you may want to share, like or retweet this particular newsletter.
_____________________
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
